A new era for antiplatelet therapy in patients with acute coronary syndrome

American Journal of the Medical Sciences

Volumn 340, Issue 5, 2010, Pages 407-411

  Dib, Chadi ^a   Hanna, Elias B ^a   Abu Fadel, Mazen S ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Adrenal insufficiency; Amenorrhea; Hypopituitarism; Hypothyroidism; Postpartum hemorrhage

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ATRIOVENTRICULAR DISSOCIATION; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG RESISTANCE; DYSPNEA; HUMAN; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; THROMBOCYTE AGGREGATION INHIBITION;

EID: 78349309100     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181ee5bfb     Document Type: Review

References (39)

1. Norgard NB, Abu-Fadel M. Comparison ofprasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vasc Health Risk Manag 2009;5:873-82.
2. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
3. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary inter-vention: a randomized controlled trial. JAMA 2002;288:2411-20.
4. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, manage-ment, and future perspectives. J Am Coll Cardiol 2007;49:1505-16.
5. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibi-tion by ketoconazole affects prasugrel and clopidogrel pharmacokinet-ics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81: 735-41.
6. Dangas G, Mehran R, Guagliumi G, et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarc-tion undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2009;54:1438-46.
7. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel respon-siveness in healthy subjects. Blood 2006;108:2244-7.
8. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymor-phisms and response to clopidogrel. N Engl J Med 2009;360:354-62.
9. Hoshino K, Horiuchi H, Tada T, et al. Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention. Circ J2009;73:336-42.
10. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005;45:1157-64.
11. Ho PM, Maddox TM, Wang L, et al. Risk ofadverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301: 937-44.
12. Cuisset T, Frere C, Quilici J, et al. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predic-tors of non response. Thromb Res 2009;123:597-603.
13. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16.
14. Mehta SR, Bassand JP, Chrolavicius S, et al. CURRENT OASIS-7: a randomized, 2X2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Presented at the European Society of Cardiology Congress, Barcelona, Spain, August 2009.
15. Angiolillo DJ, Suryadevara S, Capranzano P, et al. Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mech-anism of action and clinical development. Expert Opin Pharmacother 2008;9:2893-900.
16. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics ofprasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-84.
17. Brandt JT, Payne CD, Wiviott SD, et al. A comparison ofprasugrel and clopidogrel loading doses on platelet function: magnitude ofplate-let inhibition is related to active metabolite formation. Am Heart J 2007;153:66 e9-16.
18. Farid NA, Smith RL, Gillespie TA, et al. The disposition ofprasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007;35:1096-104.
19. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in compari-son to clopidogrel for inhibition ofplatelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007;116: 2923-32.
20. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation2009;120:2577-85.
21. Asai F, Jakubowski JA, Naganuma H, et al. Platelet inhibitory activity and pharmacokinetics ofprasugrel (CS-747) a novel thienopy-ridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Platelets 2006;17:209-17.
22. Jakubowski JA, Payne CD, Brandt JT, et al. The platelet inhibitory effects and pharmacokinetics ofprasugrel after administration ofload-ing and maintenance doses in healthy subjects. J Cardiovasc Pharmacol 2006;47:377-84.
23. Wrishko RE, Ernest CS II, Small DS, et al. Population pharmacoki-netic analyses to evaluate the influence ofintrinsic and extrinsic factors on exposure ofprasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol 2009;49:984-98.
24. Kushner FG, Hand M, Smith SC Jr, et al. Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009;120:2271-306.
25. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Compar-ison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation 2007; 116:2923-32.
26. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
27. Bhatt DL. Prasugrel in clinical practice. N Engl J Med 2009;361: 940-2.
28. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary inter-vention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-31.
29. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 2008;118:1626-36.
30. O'Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous interven-tion: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol 2009;54:678-85.
31. Murphy SA, Antman EM, Wiviott SD, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008;29:2473-9.
32. Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasug-rel-thrombolysis in myocardial infarction 38: an application of the classification system from the universal definition ofmyocardial infarc-tion. Circulation 2009;119:2758-64.
33. van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005;31:195-204.
34. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47.
35. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphos-phate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-51.
36. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopi-dogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
37. Hanna EB, Glancy DL, Saucedo JF. Antiplatelet and anticoagulant therapies in acute coronary syndromes. Cardiovasc Drugs Ther 2010; 24:61-70.
38. Rosenstein RS, Parra D. Ticagrelor versus clopidogrel in acute coro-narysyndromes. N Engl JMed2009;361:2385-6; authorreply2387-8.
39. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary interven-tion after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295:1531-8.